Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 9/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333451 | 1.00 | CA1 (0.39) | CA1CA2CA7ATMCTSK | |
| SCHEMBL4945179 | 1.00 | CA1 (0.39) | CA1CA2CA7ATMCTSK | |
| SCHEMBL29695615 | 0.92 | CA1 (0.41) | CA1CA2CA7ATMCTSK | |
| SCHEMBL6333387 | 0.92 | KDM4E (0.38) | CA1CA2CA7ATMCTSK | |
| SCHEMBL6333389 | 0.92 | KDM4E (0.38) | CA1CA2CA7ATMCTSK | |
| SCHEMBL6333383 | 0.92 | KDM4E (0.38) | CA1CA2CA7ATMCTSK | |
| SCHEMBL2013068 | 0.89 | CA1 (0.44) | CA1CA2CA7ATMCTSK | |
| SCHEMBL15178984 | 0.88 | SYK (0.41) | CA1CA2CA7ATMCTSK | |
| SCHEMBL18074469 | 0.88 | SYK (0.41) | CA1CA2CA7ATMCTSK | |
| SCHEMBL15304891 | 0.87 | CA2 (0.34) | CA1CA2CA7ATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| EP-1199306-B1 | BIARYLUREA DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6958333-B1 | Biarylurea derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-10-25 | — | — | US | disclosed |
| EP-1557168-A2 | Biarylurea Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-6919457-B2 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-6759426-B2 | RESPIRATORY SYSTREM DISORDERS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISORDERS | PFIZER INC | 2004-07-06 | — | — | US | disclosed |
| WO-2003061653-A9 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LTD (GB) | 2003-12-24 | — | — | WO | disclosed |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | PFIZER INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003061653-A1 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
| EP-1199306-A1 | BIARYLUREA DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | CA1 3429/4885CA2 2287/4885CA7 1498/4885 |
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | FGB, F2, F11 | CA1 3358/4885CA2 2606/4885CA7 2151/4885 |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | FGB, F2, F11 | CA1 3358/4885CA2 2606/4885CA7 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.